Advanced

Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis

Montiel, Francisco Sánchez; Ghazvinian, Raein LU ; Gottsäter, Anders LU and Elf, Johan LU (2017) In Thrombosis Journal 15(1).
Abstract

Background: Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients. Methods: Data from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27... (More)

Background: Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients. Methods: Data from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27 men aged 23-86 years, and 28 women aged 18-75 years) treated with DOAC because of UEDVT between 2012 and 2015 in the southernmost hospital region of Sweden with 1.3 million inhabitants in 2016. Patients were followed for 6 months. Results: During 6 months after institution of DOAC treatment there was one recurrence (2%) of DVT during treatment and two (4%) recurrences after cessation of treatment. No patient died, whereas one (2%) suffered a clinically relevant nonmajor bleeding. Conclusion: DOAC can be used in the treatment of UEDVT patients with acceptable efficacy and safety.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Direct acting oral anti coagulants, Upper extremity deep vein thrombosis, Venous thromboembolism
in
Thrombosis Journal
volume
15
issue
1
publisher
BioMed Central
external identifiers
  • scopus:85030679116
  • wos:000412086600001
ISSN
1477-9560
DOI
10.1186/s12959-017-0149-x
language
English
LU publication?
yes
id
9c3cd404-5279-4553-b006-922dbc14f595
date added to LUP
2017-11-02 14:09:16
date last changed
2018-01-16 13:25:28
@article{9c3cd404-5279-4553-b006-922dbc14f595,
  abstract     = {<p>Background: Upper extremity deep vein thrombosis (UEDVT) constitutes around 10% of all DVT, and can cause both pulmonary embolism (PE) and postthrombotic syndrome (PTS) in the arm. The incidence of secondary UEDVT is increasing due to widespread use of central venous catheters in patients with cancer and other chronic diseases. The safety and efficacy of using new direct acting oral anti coagulants (DOAC) in the treatment of UEDVT has not been systematically evaluated. Our aims were to evaulate efficacy, safety, and risk of recurrence of venous thromboembolism (VTE) during DOAC treatment in UEDVT patients. Methods: Data from the Swedish national anticoagulation registry (AuriculA) was retrospectively evaluated for all 55 patients (27 men aged 23-86 years, and 28 women aged 18-75 years) treated with DOAC because of UEDVT between 2012 and 2015 in the southernmost hospital region of Sweden with 1.3 million inhabitants in 2016. Patients were followed for 6 months. Results: During 6 months after institution of DOAC treatment there was one recurrence (2%) of DVT during treatment and two (4%) recurrences after cessation of treatment. No patient died, whereas one (2%) suffered a clinically relevant nonmajor bleeding. Conclusion: DOAC can be used in the treatment of UEDVT patients with acceptable efficacy and safety.</p>},
  articleno    = {26},
  author       = {Montiel, Francisco Sánchez and Ghazvinian, Raein and Gottsäter, Anders and Elf, Johan},
  issn         = {1477-9560},
  keyword      = {Direct acting oral anti coagulants,Upper extremity deep vein thrombosis,Venous thromboembolism},
  language     = {eng},
  month        = {10},
  number       = {1},
  publisher    = {BioMed Central},
  series       = {Thrombosis Journal},
  title        = {Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis},
  url          = {http://dx.doi.org/10.1186/s12959-017-0149-x},
  volume       = {15},
  year         = {2017},
}